Drug Profile
Research programme: IRAK-4 inhibitors - Aurigene Oncology/Curis
Alternative Names: Interleukin-1 receptor-associated kinase 4 inhibitors - Aurigene Oncology/Curis; IRAK-4 inhibitors; IRAK4 kinase inhibitors - Aurigene Oncology/CurisLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology; Curis
- Class Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Inflammation
Most Recent Events
- 31 Dec 2023 Curis files foreign patent applications for IRAK-4 inhibitory compounds before December 2023
- 31 Dec 2023 Curis in-licenses IP rights from Aurigene for IRAK-4 inhibitory compounds in the US before December 2023
- 28 May 2019 No recent reports of development identified for preclinical development in Inflammation in India (PO)